Jove
Visualize
Contact Us

Related Experiment Videos

Fatal reaction to haemaccel.

M K Freeman

    Anaesthesia
    |April 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Fatal bronchospasm occurred, likely due to an allergic reaction to Haemaccel. This case highlights potential risks associated with this artificial colloid solution.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cor pulmonale and the Pierre Robin anomaly. Airway management with a nasopharyngeal tube.

    Anaesthesia·1980
    Same author

    Responsibility of small lymphocytes for the killing effect of blood-marrow mixtures on irradiated rabbits.

    Annals of the New York Academy of Sciences·1962
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Anesthesiology
    • Pharmacology
    • Immunology

    Background:

    • Haemaccel (polygeline) is a plasma volume expander derived from bovine gelatin.
    • It is used to treat hypovolemia and shock.
    • Adverse reactions, though rare, can occur.

    Observation:

    • A patient experienced severe, fatal bronchospasm.
    • The event was temporally associated with the administration of Haemaccel.
    • No other causative agents were identified.

    Findings:

    • The bronchospasm was strongly suspected to be an allergic or hypersensitivity reaction.
    • The immune response was likely triggered by components within the Haemaccel solution.
    • This suggests a potential immunogenic property of Haemaccel.

    Implications:

    • Clinicians should be aware of the potential for severe allergic reactions to Haemaccel.
    • Careful patient monitoring is crucial during and after administration of plasma expanders.
    • Further investigation into the immunogenicity of Haemaccel may be warranted.